A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B

  • Pianko, Stephen (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/13/SHA/51
Monash Health Ref: RES-13304A
Effective start/end date12/11/2011/11/25


  • Hepatitis B
  • treatment efficacy
  • treatment safety